Datopotamab Deruxtecan, often abbreviated as DATO, represents the notable advancement in targeted cancer treatment. This novel antibody-drug conjugate joins an monoclonal antibody specifically targeting HER-2 https://zoyavges595073.wikipublicity.com/user